TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07573176: A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate Efficacy and Safety of Seltorexant as Monotherapy in Adult and Elderly Participants With Major Depressive Disorder (MDD) and an Open-label Lon

Sponsor: Janssen Research & Development, LLC · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 600 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$11,173,128

Rescue Site Savings

+$7,354,464

Unlock Full NCT07573176 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07573176 Rescue Dossier →